Co-diagnostics, INC Schedule 13G passive stakes

Armistice Capital, LLC, along with its managing member Steven Boyd, has reported beneficial ownership of 559,706 shares, representing 9.99% of the outstanding common stock of Co-Diagnostics, Inc.

Jane Street Group, LLC and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 1.7% of Co-Diagnostics, Inc. common stock as of June 30, 2026.

Jane Street Group, LLC, Jane Street Capital, LLC, and Jane Street Global Trading, LLC have collectively reported beneficial ownership of 6.4% of Co-Diagnostics, Inc. common stock.

Ayrton Capital LLC and its affiliates have reported a complete divestment of their beneficial ownership in Co-Diagnostics, Inc., now holding 0% of the common stock.

Ayrton Capital LLC, along with Alto Opportunity Master Fund and Waqas Khatri, reported a 9.70% beneficial ownership stake in Co-Diagnostics, Inc. common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a beneficial ownership of 3.7% of Co-Diagnostics, Inc.'s common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 9.9% beneficial ownership stake in Co-Diagnostics, Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 3.54% beneficial ownership in Co-Diagnostics Inc.

Orca Capital AG has reported a 4.6% beneficial ownership stake in Co-Diagnostics, Inc., holding 2,193,713 shares of common stock.

Orca Capital AG has reported a 9.9% beneficial ownership stake in Co-Diagnostics, Inc., holding 4,809,500 shares of common stock.